Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma

Steven P. Rowe; Michael A. Gorin; Hans J. Hammers; Martin G. Pomper; Mohammad E. Allaf; Mehrbod Som Javadi

doi:10.1097/RLU.0000000000000995

Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma

Steven P. Rowe, Michael A. Gorin, Hans J. Hammers, Martin G. Pomper, Mohammad E. Allaf, Mehrbod Som Javadi

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both ¹⁸F-FDG and ¹⁸F-DCFPyL PET/CT. ¹⁸F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to ¹⁸F-FDG, ¹⁸F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

Original language	English (US)
Pages (from-to)	83-85
Number of pages	3
Journal	Clinical nuclear medicine
Volume	41
Issue number	1
DOIs	https://doi.org/10.1097/RLU.0000000000000995
State	Published - Jan 1 2016

Keywords

PET/CT
metastatic renal cell carcinoma
prostate-specific membrane antigen (PSMA)

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000000995

Cite this

@article{f47308bae00e4929bcfadd121c957e53,

title = "Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma",

abstract = "Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.",

keywords = "PET/CT, metastatic renal cell carcinoma, prostate-specific membrane antigen (PSMA)",

author = "Rowe, {Steven P.} and Gorin, {Michael A.} and Hammers, {Hans J.} and Pomper, {Martin G.} and Allaf, {Mohammad E.} and Javadi, {Mehrbod Som}",

note = "Publisher Copyright: {\textcopyright} 2015 Wolters Kluwer Health, Inc.",

year = "2016",

month = jan,

day = "1",

doi = "10.1097/RLU.0000000000000995",

language = "English (US)",

volume = "41",

pages = "83--85",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma

AU - Rowe, Steven P.

AU - Gorin, Michael A.

AU - Hammers, Hans J.

AU - Pomper, Martin G.

AU - Allaf, Mohammad E.

AU - Javadi, Mehrbod Som

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

AB - Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.

KW - PET/CT

KW - metastatic renal cell carcinoma

KW - prostate-specific membrane antigen (PSMA)

UR - http://www.scopus.com/inward/record.url?scp=84951907767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951907767&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000995

DO - 10.1097/RLU.0000000000000995

M3 - Article

C2 - 26402128

AN - SCOPUS:84951907767

SN - 0363-9762

VL - 41

SP - 83

EP - 85

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 1

ER -

Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this